University of Ioannina
Μελέτη της θεραπείας με ανοσοτροποιητικά φάρμακα και βιολογικούς παράγοντες σε ασθενείς με ιδιοπαθή φλεγμονώδη νόσο των εντέρων
Abstract
dc:descriptionIntroduction: Therapeutic monitoring of infliximab correlates with improved outcomes in patients with inflammatory bowel diseases (IBD). This cross-sectional study aimed to assess the relationship between serum infliximab trough levels (TLs), antibodies-to-infliximab (ATI) and therapeutic outcomes in patients with ulcerative colitis (UC) and Crohn’s disease (CD) within a Greek population. The relationship between infliximab-related infusion reactions (IRs) and the presence of ATI was also investigated. Materials and Methods: Consecutive adult patients with IBD treated with intravenous maintenance infliximab at a Greek tertiary centre were included. Investigated therapeutic outcomes included sustained clinical remission (CR), steroid-free clinical remission (SFCR), biochemical remission (CRP <5mg/L, BR) and combined (steroid-free clinical and biochemical) remission (SFCBR). Infliximab TLs and ATI (in patients with TLs <1 μg/mL) were assessed using ELISA-based assays. Results: A total of 77 patients were enrolled (62.3% males, mean age 44 years), including 48 (62.3%) with CD, 26 (33.8%) with UC and 3 (3.9%) with unclassified colitis. The mean disease duration was 11.7 years and the mean duration of infliximab infusion was 5.1 years. Forty-seven patients (61%) had undergone treatment escalation with a decrease in infusion intervals, with a further dose escalation in 7 (9.1%) patients. Concomitant therapy was administered to 13 (16.8%) patients, with 4 (5.2%) receiving azathioprine and 9 (11.7%) corticosteroids. Mean infliximab TLs were 7.2±4.9 μg/mL, significantly correlating with treatment escalation (9.7 vs 3.6 μg/mL, p<0.001). Sixty-eight patients (88.3%) achieved CR, 62 (80.5%) achieved SFCR, 48 (62.3%) achieved BR and 43 (55.8%) achieved SFCBR. Mean infliximab TLs were higher, though not significantly, among responders. In the subgroup analysis, among patients without treatment escalation, 27 (90%) achieved CR, 25 (83.3%) achieved SFCR, 22 (73.3%) achieved BR and 19 (63.3%) achieved SFCBR. Mean infliximab TLs were significantly higher in patients with BR (4.2 vs 0.8 μg/mL, p=0.020) and SFCBR (4.3 vs 1.5 μg/mL, p=0.035). ROC analysis indicated that TLs could predict SFCBR (p=0.016) with good accuracy (AUC 0.768, 95% Cl: 0.584=0.952), with an optimal TL cut-off at 3.4 μg/mL. Among patients with treatment escalation, 41 (87.2%) achieved CR, 37 (78.7%) achieved SFCR, 26 (55.3%) achieved BR and 24 (51.1%) achieved SFCBR. ROC analysis indicated that TLs could predict SFCBR (p=0.018) with a fair accuracy (AUC 0.653, 95% CI: 0.527=0.755), with an optimal TL cut-off at 11 μg/mL. Of the 20 patients with TLs <1 μg/mL who had ATI measured, 10 had positive ATI. Among these 20 patients, 9 achieved combined remission, with 4 having positive ATI. In the 11 patients who did not achieve combined remission, 6 (54.5%) had positive ATI, indicating non-response to infliximab due to immunogenicity. Twenty-one patients (27.3%) reported adverse events, with 8 (10.4%) experiencing IRs attributed to infliximab. There was a tendency for IRs to correlate with ATI presence; 4 out of 5 patients who had IRs and measured ATI were positive, while out of 10 patients with positive ATI, 4 reported an IR, compared to 1 out of 10 patients with negative ATI (p=0.152).Conclusions: In this study we have shown that infliximab TLs are correlated with treatment escalation. Higher TLs seem to result in positive therapeutic outcomes. Furthermore, patients undergoing treatment escalation seem to benefit from higher infliximab TLs for achieving clinical and biochemical remission. Immunogenicity, as indicated by ATI, contributes to loss of response in some patients with low infliximab TLs. There is also a trend indicating a correlation between ATI and IRs.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Orfanidou, Afroditi
- Ορφανίδου, Αφροδίτη
Subjects
dc:subject × 24- Ιδιοπαθή φλεγμονώδη νοσήματα εντέρου
- Βιολογικοί παράγοντες
- Θεραπεία με αντι-TNFα παράγοντες
- Αντι-TNF-α παράγοντες
- Επίπεδα φαρμάκων
- Θεραπευτική φαρμακευτική παρακολούθηση
- Θεραπευτική παρακολούθηση ινφλιξιμάμπης
- Inflammatory bowel diseases (IBD)
- Biologic agents
- Treatment with anti-TNFa agents
- Anti-TNF agents
- Drug levels
- Therapeutic drug monitoring
- Therapeutic infliximab monitoring
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Γαστροεντερολογία
- Βασική Ιατρική
- Φαρμακολογία και Φαρμακευτική
- Clinical Medicine
- Medical and Health Sciences
- Gastroenterology
- Basic Medicine
- Pharmacology and Pharmacy
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/57790